Key result
Conventional chemotherapy has a favorable impact on selected patients with primary high-risk bone and soft-tissue sarcomas and is frequently the most appropriate first-line therapy for recurrent disease.
Conventional chemotherapy is an integral component of care for aggressive and recurrent sarcomas, with novel agents currently in development.
May inform chemotherapy decisions in high-risk sarcomas; leaves open optimal integration with novel agents.
Conventional chemotherapy can have a favorable impact on the natural history of disease for selected patients with primary high-risk bone and soft-tissue sarcomas. In particular, multidrug regimens are integral to the care of patients with the most aggressive histologies, including Ewing sarcoma, osteosarcoma, and non-pleomorphic rhabdomyosarcoma. Appropriately selected patients with high-risk, clinically localized soft-tissue sarcomas may also benefit from histology-tailored adjuvant or neoadjuvant therapy. For patients with recurrent disease, conventional chemotherapy is frequently the most appropriate first-line therapy; active drugs are discussed at length. Several new promising cytotoxic chemotherapeutic agents are currently under development, including aldoxorubicin, TH-302, and trabectedin.
No takes yet. Share an insight, caveat, or question.
David A. Liebner (2015) conducted a review in Primary and recurrent sarcoma. Conventional chemotherapy was evaluated. Conventional chemotherapy has a favorable impact on selected patients with primary high-risk bone and soft-tissue sarcomas and is frequently the most appropriate first-line therapy for recurrent disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: